GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HPGC Renmintongtai Pharmaceutical Corp (SHSE:600829) » Definitions » Debt-to-Equity

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Debt-to-Equity : 0.33 (As of Sep. 2024)


View and export this data going back to 1994. Start your Free Trial

What is HPGC Renmintongtai Pharmaceutical Debt-to-Equity?

HPGC Renmintongtai Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥925 Mil. HPGC Renmintongtai Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥20 Mil. HPGC Renmintongtai Pharmaceutical's Total Stockholders Equity for the quarter that ended in Sep. 2024 was ¥2,874 Mil. HPGC Renmintongtai Pharmaceutical's debt to equity for the quarter that ended in Sep. 2024 was 0.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for HPGC Renmintongtai Pharmaceutical's Debt-to-Equity or its related term are showing as below:

SHSE:600829' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07   Med: 0.26   Max: 0.61
Current: 0.33

During the past 13 years, the highest Debt-to-Equity Ratio of HPGC Renmintongtai Pharmaceutical was 0.61. The lowest was 0.07. And the median was 0.26.

SHSE:600829's Debt-to-Equity is ranked worse than
54.53% of 827 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs SHSE:600829: 0.33

HPGC Renmintongtai Pharmaceutical Debt-to-Equity Historical Data

The historical data trend for HPGC Renmintongtai Pharmaceutical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HPGC Renmintongtai Pharmaceutical Debt-to-Equity Chart

HPGC Renmintongtai Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.34 0.60 0.52 0.37

HPGC Renmintongtai Pharmaceutical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.37 0.41 0.39 0.33

Competitive Comparison of HPGC Renmintongtai Pharmaceutical's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, HPGC Renmintongtai Pharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HPGC Renmintongtai Pharmaceutical's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HPGC Renmintongtai Pharmaceutical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where HPGC Renmintongtai Pharmaceutical's Debt-to-Equity falls into.



HPGC Renmintongtai Pharmaceutical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

HPGC Renmintongtai Pharmaceutical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

HPGC Renmintongtai Pharmaceutical's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HPGC Renmintongtai Pharmaceutical  (SHSE:600829) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


HPGC Renmintongtai Pharmaceutical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of HPGC Renmintongtai Pharmaceutical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


HPGC Renmintongtai Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
No. 76 Hengshan Road, Nangang District, Heilongjiang Province, Harbin, CHN, 150076
HPGC Renmintongtai Pharmaceutical Corp, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co Ltd is engaged in the production and sale of pharmaceuticals products in China.
Executives
Yue Xian Zhi senior management
Zhang Li Jun Director

HPGC Renmintongtai Pharmaceutical Headlines

No Headlines